Brussels, 17/06/2022 (Agence Europe) – On Wednesday 15 June, the European Medicines Agency (EMA) announced the start of the ongoing evaluation of a messenger RNA vaccine against SARS-CoV-2 developed by Pfizer-BioNTech and adapted to one or more variants of concern of SARS-CoV-2. This procedure, which precedes and accelerates the formal evaluation phase, will first focus on the manufacturing aspects of the vaccine. The EMA will then evaluate the data as soon as it is provided by...